Scholars Central

Conference abstractPublished 28 Mar 2019

Guideline on good pharmacovigilance practices Module V-Risk management systems (Revision 2): Updates and feedback

Authors: Fawad Piracha

Regeneron Pharmaceuticals, Inc, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The concept of benefit-risk balance has evolved in the realm of public health and the pharmaceutical industry, giving rise to robust risk management systems, as mechanisms by which to help promote a favorable benefitrisk balance to regulators, Healthcare Professionals (HCPs) and patients. In addition to supporting the submission dossier for a Marketing Authorization Application (MAA), the EMA Risk Management Plan (RMP) serves an important role for promulgating risks of marketed products to stakeholders, including the public. Guideline on Good Pharmacovigilance Practices (GVP) Module Vâ??Risk Management Systems (Revision 2) and the corresponding revision to the RMP template, have improved the regulatory framework and scope of the RMP, giving rise to an enhanced document that is more focused yet comprehensive. The adoption and implementation of the revised guideline and template have been coupled with generally positive feedback from regulators, notwithstanding challenges that accompany change.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Clinical Trials.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical Trials
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Fawad Piracha”